MA30981B1 - Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments - Google Patents

Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments

Info

Publication number
MA30981B1
MA30981B1 MA31971A MA31971A MA30981B1 MA 30981 B1 MA30981 B1 MA 30981B1 MA 31971 A MA31971 A MA 31971A MA 31971 A MA31971 A MA 31971A MA 30981 B1 MA30981 B1 MA 30981B1
Authority
MA
Morocco
Prior art keywords
disorders
oxadiazol
sulfonyl
phenyl
derivatives
Prior art date
Application number
MA31971A
Other languages
English (en)
Inventor
Stefanie Keil
Matthias Urmann
Karl Schoenafinger
Wolfgang Wendler
Maike Glien
Hans-Ludwig Schaefer
Eugen Falk
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37998695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30981(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA30981B1 publication Critical patent/MA30981B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

L'INVENTION PORTE SUR DES SULFONYL-PHÉNYL-OXADIAZOLONES ET SUR LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET DÉRIVÉS PHYSIOLOGIQUEMENT FONCTIONNELS MONTRANT UNE ACTIVITÉ AGONISTE DE PPARDELTA OU DE PPARDELTA ET PPARGAMMA. ON DÉCRIT DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE I, DANS LAQUELLE LES RADICAUX SONT TELS QUE DÉFINIS, ET LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET DES PROCÉDÉS PERMETTANT DE LES PRÉPARER. LES COMPOSÉS SONT APPROPRIÉS POUR LE TRAITEMENT ET/OU LA PRÉVENTION DE TROUBLES DU MÉTABOLISME DES ACIDES GRAS ET DES TROUBLES DE L'UTILISATION DU GLUCOSE AINSI QUE DE TROUBLES DANS LESQUELS LA RÉSISTANCE À L'INSULINE EST MISE EN JEU ET LA DÉMYÉLINISATION ET AUTRES TROUBLES NEURODÉGÉNÉRATIFS DU SYSTÈME NERVEUX CENTRAL ET PÉRIPHÉRIQUE.
MA31971A 2006-12-14 2009-06-10 Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments MA30981B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06025880A EP1932843A1 (fr) 2006-12-14 2006-12-14 Dérivés de sulfonyl-phenyl-2H(1,2,4) oxadiazole-5-one, procédés de préparation de ceux-ci et leur usage sous forme de médicaments

Publications (1)

Publication Number Publication Date
MA30981B1 true MA30981B1 (fr) 2009-12-01

Family

ID=37998695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31971A MA30981B1 (fr) 2006-12-14 2009-06-10 Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments

Country Status (24)

Country Link
US (1) US8173674B2 (fr)
EP (2) EP1932843A1 (fr)
JP (1) JP2010512352A (fr)
KR (1) KR20090087922A (fr)
CN (1) CN101558064A (fr)
AR (1) AR064299A1 (fr)
AU (1) AU2007331805A1 (fr)
BR (1) BRPI0720416A2 (fr)
CA (1) CA2672347A1 (fr)
CL (1) CL2007003614A1 (fr)
CO (1) CO6210729A2 (fr)
CR (1) CR10778A (fr)
EC (1) ECSP099409A (fr)
MA (1) MA30981B1 (fr)
MX (1) MX2009005535A (fr)
NO (1) NO20092293L (fr)
PE (1) PE20081404A1 (fr)
RU (1) RU2009126745A (fr)
SV (1) SV2009003293A (fr)
TN (1) TN2009000242A1 (fr)
TW (1) TW200843749A (fr)
UY (1) UY30783A1 (fr)
WO (1) WO2008071311A1 (fr)
ZA (1) ZA200903160B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2288607B1 (fr) * 2008-06-09 2014-09-24 Sanofi Sulfonamides comprenant un hétérocycle et un groupe de tête oxadiazolone, procédés pour les préparer et leur utilisation comme produits pharmaceutiques
NZ589694A (en) * 2008-06-09 2012-05-25 Sanofi Aventis Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
NZ701469A (en) * 2012-05-25 2017-06-30 Corcept Therapeutics Inc Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US20190135798A1 (en) 2015-11-02 2019-05-09 Basf Se Substituted Oxadiazoles for Combating Phytopathogenic Fungi
EP3165094A1 (fr) 2015-11-03 2017-05-10 Basf Se Oxadiazoles substitués pour lutter contre les champignons phytopathogènes
US20180317490A1 (en) 2015-11-04 2018-11-08 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
KR20180083419A (ko) 2015-11-19 2018-07-20 바스프 에스이 식물병원성 진균을 퇴치하기 위한 치환 옥사디아졸
JP2019502661A (ja) 2015-11-19 2019-01-31 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 植物病原菌を駆除するための置換オキサジアゾール
US10986839B2 (en) 2016-04-11 2021-04-27 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
WO2017211652A1 (fr) 2016-06-09 2017-12-14 Basf Se Oxadiazoles substitués pour lutter contre des champignons phytopathogènes
WO2017211650A1 (fr) 2016-06-09 2017-12-14 Basf Se Oxadiazoles substitués pour lutter contre des champignons phytopathogènes
EP3555056A1 (fr) 2016-12-19 2019-10-23 Basf Se Oxadiazoles substitués pour lutter contre des champignons phytopathogènes
EP3339297A1 (fr) 2016-12-20 2018-06-27 Basf Se Oxadiazoles substitués pour lutter contre les champignons phytopathogènes
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
WO2018219797A1 (fr) 2017-06-02 2018-12-06 Basf Se Oxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes
EP3642187A1 (fr) 2017-06-19 2020-04-29 Basf Se 2-[[5-(trifluorométhyl)-1,2,4-oxadiazol-3-yl]aryloxy](thio)acétamides pour lutter contre des champignons phytopathogènes
WO2019002158A1 (fr) 2017-06-30 2019-01-03 Basf Se Trifluorométhyloxadiazoles substitués utilisés pour lutter contre des champignons phytopathogènes
EP3684761A1 (fr) 2017-09-18 2020-07-29 Basf Se Trifluorométhyloxadiazoles substitués permettant de lutter contre des champignons phytopathogènes
WO2019101511A1 (fr) 2017-11-23 2019-05-31 Basf Se Trifluorométhyloxadiazoles substitués permettant de lutter contre des champignons phytopathogènes
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN113194931B (zh) 2018-12-19 2023-11-10 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
NZ778399A (en) 2019-02-22 2024-11-29 Corcept Therapeutics Inc Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
KR102649355B1 (ko) * 2020-03-31 2024-03-19 주식회사 엘지화학 췌도 이식 보호용 조성물
EP4157276A4 (fr) 2020-05-27 2024-06-12 Corcept Therapeutics Incorporated Administration concomitante de relacorilant de modulateur du récepteur de glucocorticoïde et de paclitaxel, double substrat de cyp2c8 et cyp3a4
WO2022134033A1 (fr) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Procédés de préparation de modulateurs du récepteur des glucocorticoïdes d'azadécaline fusionnée hétéroaryle-cétone
WO2024077169A1 (fr) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations de modulateurs des récepteurs des glucocorticoïdes
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
DE10222034A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Tetrahydroisochinolin-Derivate
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
JPWO2004080943A1 (ja) * 2003-03-11 2006-06-08 小野薬品工業株式会社 シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
US20060258683A1 (en) 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
DE10335449A1 (de) 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
EP1586573B1 (fr) * 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques

Also Published As

Publication number Publication date
TN2009000242A1 (en) 2010-10-18
ECSP099409A (es) 2009-07-31
US20090298871A1 (en) 2009-12-03
SV2009003293A (es) 2009-10-27
NO20092293L (no) 2009-09-08
EP2102198A1 (fr) 2009-09-23
AU2007331805A1 (en) 2008-06-19
US8173674B2 (en) 2012-05-08
WO2008071311A1 (fr) 2008-06-19
EP2102198B1 (fr) 2015-02-25
MX2009005535A (es) 2009-06-05
TW200843749A (en) 2008-11-16
AR064299A1 (es) 2009-03-25
UY30783A1 (es) 2008-07-31
EP1932843A1 (fr) 2008-06-18
CN101558064A (zh) 2009-10-14
CL2007003614A1 (es) 2008-06-20
BRPI0720416A2 (pt) 2013-12-31
CO6210729A2 (es) 2010-10-20
CR10778A (es) 2009-06-24
JP2010512352A (ja) 2010-04-22
RU2009126745A (ru) 2011-01-20
CA2672347A1 (fr) 2008-06-19
PE20081404A1 (es) 2008-11-04
ZA200903160B (en) 2010-10-27
KR20090087922A (ko) 2009-08-18

Similar Documents

Publication Publication Date Title
MA29807B1 (fr) Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques.
MA32323B1 (fr) Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques
MA29809B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques
MA29810B1 (fr) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques
TN2009000242A1 (en) Sulfonyl-phenyl-2h-[1,2,4]oxodiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals
MA31841B1 (fr) Modulateurs du gpr40 à biphényle substitué
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MX2010006647A (es) Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos.
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA29379B1 (fr) Derives de pyrrolidine 3,4-substitues pour le traitement de l'hypertension
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
NZ540288A (en) Target for therapy of cognitive impairment
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
EP4000609B1 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies osseuses
MA27741A1 (fr) Derives diarylcycloalkyles , procede pour leur production, et leur utilisation en tant que medicaments
MA38229B1 (fr) Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
JP2015518483A (ja) ラクトース不耐症を処置する方法
MA32506B1 (fr) Nouveaux composes
FR2939135B1 (fr) Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
CA3137190A1 (fr) Compositions et methodes pour inhiber la croissance de cellules sanguines cancereuses
MA31079B1 (fr) Sel de potassium cristallin d'analogues de la lipoxine a4
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
MA30540B1 (fr) Derives de quinolines et compositions pharmaceutiques de ces derives.
MA29812B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques